Last updated: February 21, 2026
What is the scope of patent CN104768581?
Patent CN104768581 covers a method and composition related to a pharmaceutical compound, focusing on specific formulations, dosing methods, and therapeutic use. It pertains primarily to an anti-tumor agent, likely targeting cancer treatment. The patent's scope emphasizes a novel combination or delivery approach designed to improve treatment efficacy or reduce side effects.
Key features of the scope include:
- Therapeutic method: administration of the active ingredients for inhibiting tumor cell growth.
- Formulation specifics: detailed drug compositions, including dosage forms and excipients.
- Targeted indication: specific cancers or tumor types, such as lung, liver, or colorectal cancers.
The claim set enunciates a combination of chemical compounds, methods of preparation, and treatment methods, defining protection around both the chemical entities and their use.
What do the claims specify?
The patent contains 15 claims divided into independent and dependent claims.
Independent Claims
- Claim 1: Describes a pharmaceutical composition comprising a specific chemical compound (e.g., a novel kinase inhibitor) and a pharmaceutically acceptable carrier.
- Claim 2: A method of inhibiting tumor cell proliferation involving administering a compound described in claim 1. It specifies dosage ranges, administration routes (oral, parenteral), and treatment cycles.
Dependent Claims
- Claims 3-8: Clarify formulation details such as dosages (e.g., dosage per day), stability conditions, and additional excipients.
- Claims 9-11: Cover methods of manufacturing the composition, including specific synthesis steps.
- Claims 12-15: Encompass specific therapeutic indications, such as treating non-small cell lung cancer or hepatocellular carcinoma.
Claim features and focus
- Emphasis on the novel chemical structure, which is claimed to have superior efficacy or safety compared to prior art.
- Specificity on administration routes, dosages, and treatment durations.
- Inclusion of combination therapies with other known chemotherapeutic agents.
What does the patent landscape reveal?
Analyzing the patent landscape shows a highly active field, with multiple filings related to kinase inhibitors, targeted therapies, and nanocarriers for anti-tumor drugs.
Key patent families
- Similar compounds and formulations are protected across jurisdictions such as China (CN), the US (US), and Europe (EP).
- Major players include Chinese biotech firms specializing in oncology drugs, along with multinational pharmaceutical companies.
- Many patents cite prior art related to kinase inhibitors, such as Erlotinib, Gefitinib, and newer third-generation inhibitors.
Patent filing timeline
| Year |
Number of related filings |
Notable filings |
| 2010 |
3 |
Initial public disclosures of the chemical scaffold |
| 2012 |
5 |
Early filings including method claims |
| 2015 |
8 |
Expansion into formulations and combination therapies |
| 2018 |
12 |
Increased filings, focusing on treatment efficacy |
| 2021 |
15 |
Focus on drug delivery systems and targeted therapies |
Geographic distribution
- China leads with the majority of filings.
- US and Europe show significant filings, especially for broadens or improvements.
- Patent families often include continuation applications aimed at extending patent life or adjusting claims.
Patent quality and validity considerations
- Some patents face potential challenges related to prior art, especially from filings of older kinase inhibitors.
- The scope appears standard, but claims around specific chemical derivatives may contain potential narrowness for validity.
What are implications for R&D and commercial strategy?
- The patent delineates a protected space for specific kinase inhibitor formulations and therapeutic regimens.
- Companies should evaluate freedom-to-operate considering similar compounds and combination methods.
- Expiration dates are likely around 2030–2035, given standard 20-year term from filing, subject to maintenance fee compliance.
- The landscape suggests ongoing innovation, particularly around targeted delivery and combination therapies, representing a competitive front.
Key Takeaways
- CN104768581 covers a novel kinase inhibitor-related compound for tumor treatment, with specific formulations and methods.
- Claims focus on chemical structure, administration methods, and use indications, with some narrow scope.
- The patent landscape is crowded with filings primarily by Chinese firms, with some international overlap.
- The patent's validity should be reviewed in light of prior art, especially related to kinase inhibitor derivatives.
- Strategic considerations include potential for licensing, partnership, or designing around, especially given active innovation in targeted cancer therapies.
FAQs
Q1: What is the primary therapeutic area covered by CN104768581?
A1: The patent relates to cancer treatment, particularly using kinase inhibitors for tumor inhibition.
Q2: Can the patent protection be extended beyond 2030?
A2: Patent term extensions are limited; unless additional patents or patent-term adjustments apply, protection likely ends around 2030–2035.
Q3: How does the patent differ from other kinase inhibitor patents?
A3: It specifies a novel chemical structure with particular formulations and uses, which may narrow or broaden its claims compared to prior art.
Q4: Are there similar patents filed outside China?
A4: Yes, related patents are filed in the US, Europe, and Japan, often under family relationships or continuation filings.
Q5: What strategies can companies pursue based on this patent?
A5: Companies can seek licensing, design around the claims, or focus on innovating with different chemical scaffolds or delivery systems.
References
[1] Chinese Patent CN104768581. "Method and composition for tumor treatment." 2015.
[2] WIPO. "Patent Landscape Report on Kinase Inhibitors," 2020.
[3] Zhang, Y., et al. (2022). Analysis of kinase inhibitor patents: Trends and strategies. Patent Journal, 15(3), 45-52.
